CBD Guangzhou 2025 Wraps Up with International Attendance Rising by 47.22%

The 27th China (Guangzhou) International Building Decoration Fair (CBD Fair Guangzhou), held in tandem with the Guangzhou International Bath & Sanitary Ware Fair (CBS Fair), concluded on July 11. Spanning 300,000 square meters, the fair hosted nearly 2,000 exhibitors and over 70 high-level forums and conferences. A total of 205,621 professional attendees from 145 countries […]

SMU issues its inaugural Sustainability Bond, raising S$150 million to advance environmental and social initiatives

Singapore Management University (SMU) today announced that it has completed the issuance of a S$150 million Sustainability Bond. The proceedsof the Bond are earmarked for financing and refinancing green and social projects that deliver clear environmental and social benefits, as guided by SMU's newly established Sustainable Financing Framework. https://mma.prnewswire.com/media/2214752/Singapore_Management_University_Logo.jpg The Sustainability Bond, the first such

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

— This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China. — XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Neogen Corporation (NEOG) Investors of September 16, 2025 Deadline

NEW YORK, NY / ACCESS Newswire / July 27, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=158363&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Neogen Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEOG

NEW YORK CITY, NY / ACCESS Newswire / July 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025, inclusive (the "Class Period"). A

PepGen Inc. (PEPG) Lawsuit – Investors Urged to Contact Levi & Korsinsky Before August 8, 2025

NEW YORK, NY / ACCESS Newswire / July 27, 2025 / If you suffered a loss on your PepGen Inc. (NASDAQ:PEPG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=158362&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

— Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD — Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop up to 12

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Reckitt Benckiser Group plc (RBGLY)

NEW YORK, NY / ACCESS Newswire / July 27, 2025 / If you suffered a loss on your Reckitt Benckiser Group plc (OTCQX:RBGLY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/reckitt-benckiser-group-plc-lawsuit-submission-form?prid=158361&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Scroll to Top